Nektar Therapeutics (NASDAQ:NKTR) insider has recently participated in insider trading activity. SVP & Chief Medical Officer, Gergel Ivan P. sold 556 shares for $6,628 via one transaction Feb 17. Another notable insider trading was done by Nicholson John on Feb 17, who is the SVP & Chief Financial Officer. The insider Sold 963 shares at an average price of $11.92. Moreover, an insider selling of 2,147 shares was carried out by ROBIN HOWARD W, President& CEO, on Feb 17. Following the transaction, the insider now owns 13,478 shares in total. SVP & Chief Accounting Officer Thomsen Jillian B. sold 716 shares for $8,535 through one transaction Feb 17. Following this sale, this insider’s stake in the company comprises 5,158 shares, priced at $58491.72 as of Thursday.
The stock has experienced a total of 11 insider trades in the past three months. These trades include 11 sell activities and 0 buy trades. Furthermore, over the past 12 months, the stock was traded 33 times by insiders. In 33 of these trades, the insider was a seller while an employee of the company was the buyer in just 0 instances.
Nektar Therapeutics (NKTR) on February 1, 2016 announced the publication in Clinical Cancer Research of pre-clinical findings for NKTR-214. The paper, titled “NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models,” (Charych et al., Clin Cancer Res, doi:10.1158/1078-0432.CCR-15-1631) documents a broad set of pre-clinical data supporting the clinical advancement of NKTR-214. Among the findings reported, treatment with NKTR-214 led to durable and specific anti-tumor immunity in multiple syngeneic mouse models both as a single agent and as combination therapy with checkpoint inhibitors. In addition, treatment with single-agent NKTR-214 in tumor-bearing mice resulted in a controlled, sustained, and biased T-cell activation leading to a 450:1 mean ratio of CD8-positive effector T cells to T-regulatory cells in the tumor microenvironment, while maintaining more balanced ratios in non-tumor tissues and circulation.
“NKTR-214 allows us to capture and harness the power of the IL-2 biological pathway, which is known to promote T cell growth, to stimulate the body’s own immune system to target and fight cancer. The design of NKTR-214 gives it a combination of biophysical, biochemical, and pharmacological properties that translate into a desirable anti-tumor immune profile,” said Stephen Doberstein, Ph.D., Senior Vice President and Chief Scientific Officer of Nektar Therapeutics.
“We are pleased that the unique mechanism, efficacy and safety of NKTR-214 are now described and published in a prestigious peer-reviewed journal that is widely read by oncologists, scientists and physician-scientists,” said Dr. Doberstein. “We are continuing to advance NKTR-214 in an ongoing Phase 1/2 clinical trial in cancer patients and we expect to have preliminary top-line results from the first stage of this study in the second half of 2016.”
0 yorum:
Yorum Gönder